1. P-53 Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial. (April 2023) Authors: Pittock, S.; Barnett, M.; Bennett, J.L.; Berthele, A.; de Sèze, J.; Levy, M.; Nakashima, I.; Oreja-Guevara, C.; Palace, J.; Paul, F.; Pozzilli, C.; Allen, K.; Mashhoon, Y.; Yountz, M.; Kim, H.J. Journal: Clinical neurophysiology Issue: Volume 148(2023) Page Start: e32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-59 Association of B cell subsets and aquaporin-4 antibody titers with disease activity in participants in the N-MOmentum trial receiving inebilizumab treatment. (April 2023) Authors: Paul, F.; Pittock, S.; Kim, H.J.; Smith, M.; Rees, W.; Patterson, K.; Cree, B.; Bennett, J. Journal: Clinical neurophysiology Issue: Volume 148(2023) Page Start: e35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗